

Lung clearance index: should we really go back to nitrogen washout?

To the Editor:

A recent editorial in the *European Respiratory Journal* [1] recognises that the fundamental scientific data on lung clearance index (LCI) obtained by sulfur hexafluoride (SF₆) multiple-breath washout (MBW) have paved the way for clinical use of LCI. Although the editorial stresses the need for standardisation, it also appears to suggest that SF₆ can be replaced by nitrogen (N₂) as the washout gas.

We (Innovision ApS, Odense, Denmark) are the manufacturer of the AMIS 2000 medical mass spectrometer system that, using user-specific software and hardware, was adapted to perform MBW. The AMIS 2000-based devices are now considered the “gold standard” device for SF₆ LCI measurements in cystic fibrosis patients by opinion leaders in the field [2]. This device has been used in the vast majority of studies demonstrating the clinical value of SF₆ LCI in cystic fibrosis patients, with one recent notable exception: the demonstration of the change in LCI caused by Ivacaftor in cystic fibrosis patients with normal forced expiratory volume in 1 s, where a prototype version of our other system, Innocor, adapted for open-circuit SF₆ LCI, was used [3].

The AMIS 2000 adapted MBW system is too complex and too expensive for routine clinical use, and the LCI version and the required SF₆ gas mixture have no regulatory approval (CE mark or US Food and Drug Administration approval). To facilitate the clinical availability of SF₆-based MBW, we have introduced the Innocor system, which, together with the gases used, is approved for clinical use and provides a much less complex and cheaper alternative to the mass spectrometer system.

In the light of the strong emphasis on standardisation in the editorial, we find the suggestion to replace SF₆ with N₂ surprising, as this is a major change both from a technological and a physiological standpoint for the following reasons. 1) As N₂ cannot be measured by clinically available technologies, it is necessary to rely on indirect measurements, *i.e.* assuming that whatever is not recorded as oxygen (O₂) or carbon dioxide (CO₂) must be N₂. At the LCI point, where the N₂ concentration is only ~2%, the ability to accurately identify the N₂ concentration is significantly below that recommended by the expert consensus statement to which the editorial refers [2]. 2) Washout with 100% O₂ is not equivalent to that performed with room air. During N₂ washout using 100% O₂, gas viscosity changes by ≥10%, which causes a significant dynamic change in the gas analyser delay time during the test and affects flow resistance in the upper airways. O₂ flow across the alveolar membrane in poorly ventilated regions with end-capillary O₂ saturations <98% will also be affected when breathing 100% O₂. As this effect is smaller in well ventilated regions, distribution of ventilation will change. 3) As N₂ is not insoluble in blood and tissue, the washout curve is affected by a simultaneous washout of N₂ from blood and tissue (back diffusion).

Does all of this matter? Mathematically, the use of indirect measurement of N₂ amplifies the relative measurement error in the sum of CO₂ and O₂ concentrations at the LCI point by a factor of 49. Assuming no measurement error in CO₂:

$$\text{Indirect N}_2 \text{ at 2\%} = 100\% - 98\% \pm \text{O}_2 \text{ measurement error at 98\%}$$

At a relative error in O₂ measurement of 0.2%:

$$\text{Indirect N}_2 = 2 \pm 0.196\%$$

This means that if there is a relative measurement error in the sum of O₂ and CO₂ concentrations of, say, ±0.2% (as seen with the best O₂ analysers), the relative error in the N₂ concentration at the end of the washout will be ±10%, far in excess of that recently recommended [2].

As recognised by the consensus statement [2], the physiological impact of the use of 100% O₂ is unclear: “Thresholds at which factors such as age, sleep state and sedation interact with 100% O₂ to affect breathing pattern remain unclear”.

With a reference to a study published in 1953, the consensus statement [2] states that only limited data are available on N₂ back diffusion. However, a much more recent study [4] has shown a very significant N₂ back diffusion from blood and tissue within the time frame of a normal washout test. The data from this study imply that almost 25% of the N₂ in the lungs at the LCI point stems from back diffusion of N₂.

A recent study [5] has compared N₂ LCI with SF₆ LCI obtained with the gold standard method. Significant differences were found, and the authors concluded that independent normative values are required and that interventional studies are needed to clarify the role of N₂ LCI as an outcome measure in clinical trials in cystic fibrosis patients. The limits of agreement between N₂ and SF₆ LCI in cystic fibrosis patients were >7 LCI units, far in excess of the treatment related change reported in the Ivacaftor study of 2.1 units [3].

Finally, both the editorial [1] and the consensus statement [2] reported that the SF₆ mixture required to perform LCI testing is often not universally available and not approved. This is a misunderstanding. The mixture used with the Innocor system is an off-the-shelf, 150-mL gas tank in the European Union, the USA, Canada and in all other European countries where Innocor is used.

If the reference for clinical use of the LCI test is the scientific data obtained with the gold standard mass spectrometer device over many years of research, the suggestion to switch to N₂ LCI is premature and scientifically unfounded. Notwithstanding the well recognised problems of indirect N₂ measurement and the physiological effects of pure O₂, recent research has also highlighted that N₂ back diffusion may be much more important than previously thought.



@ERSpublications

Multiple-breath washout: nitrogen or sulfur hexafluoride? <http://ow.ly/pUW49>

Jørgen G. Nielsen
Innovision ApS, Odense, Denmark.

Correspondence: J.G. Nielsen, Innovision ApS, Lindvedvej 75, 5260 Odense S, Denmark. E-mail: jgn@innovision.dk

Received: April 19 2013 | Accepted after revision: July 31 2013

Conflict of interest: Disclosures can be found alongside the online version of this article at www.erj.ersjournals.com

References

- 1 Schulzke SM, Frey U. Consensus statement on inert gas washout measurement: at the threshold of clinical use. *Eur Respir J* 2013; 42: 500–502.
- 2 Robinson PD, Latzin P, Verbanck S, *et al.* Consensus statement for inert gas washout measurement using multiple- and single- breath tests. *Eur Respir J* 2013; 41: 507–522.
- 3 Ratjen FA, Sheridan H, Lee P-S, *et al.* Lung clearance index as an endpoint in a multicenter randomized control trial of Ivacaftor in subjects with cystic fibrosis who have mild lung disease. *Am J Respir Crit Care Med* 2012; 185: A2819.
- 4 Pendergast DR, Senf C, Lundgren CE. Is the rate of whole-body nitrogen elimination influenced by exercise? *Undersea Hyperb Med* 2012; 39: 595–604.
- 5 Jensen R, Stanojevic S, Gibney K, *et al.* Multiple breath nitrogen washout: a feasible alternative to mass spectrometry. *PLoS One* 2013; 8: e56868.

Eur Respir J 2014; 43: 655–656 | DOI: 10.1183/09031936.00069913 | Copyright ©ERS 2014

From the authors:

We thank J.G. Nielsen for his comments about our editorial related to the consensus statement for inert gas washout measurement using multiple- and single-breath tests recently published in the *European Respiratory Journal* [1, 2]. Given that we are unable to identify relevant new information concerning the topic at hand, we prefer not to add any further comments and kindly refer to the previously mentioned, very elaborate, consensus statement [2].



@ERSpublications

Consensus statement for inert gas washout measurement <http://ow.ly/rm6nI>

Sven M. Schulzke and Urs Frey
University Children's Hospital Basel (UKBB), Basel, Switzerland.

Correspondence: S.M. Schulzke, Dept of Neonatology, University Children's Hospital Basel (UKBB), Spitalstrasse 33, CH-4056 Basel, Switzerland. E-mail: sven.schulzke@unibas.ch

Received: Nov 20 2013 | Accepted: Nov 21 2013

Conflict of interest: None declared.